Tuesday, May 7, 2019 Daily Archives

Merck injects $1bn into Virginia site to support HPV vaccines

Merck & Co. will invest $1 billion over the next three years to increase production of its human papillomavirus (HPV) vaccine Gardasil at its Rockingham County site. Charlie McCurdy, a spokesperson for Merck & Co., confirmed to Bioprocess Insider his firm has committed to expand the Elkton facility in Rockingham County, Virginia facility to meet global demand for its HPV vaccines Gardasil and Gardasil 9. The $1 billion (€900 million) investment will be spread over the next three years to…

Alnylam: ‘Onpattro will springboard us into a global biopharma firm’

Alnylam says it is on course to becoming “a global multiproduct commercial biopharma company” by 2020 as sales of its messenger RNA interference therapeutic Onpattro (patisiran) begin to ramp-up. Alnylam Pharmaceuticals made history in August 2018 when Onpattro (patisiran), its product for the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis, became the first small interfering ribonucleic acid (siRNA) treatment to be approved by the US Food and Drug Administration (FDA). Reporting its first quarter 2019 financials, the firm described the milestone…

Buoyed by CGT growth, Bio-Techne plans plant to supply $200m of reagents

Bio-Techne will invest $40 million to construct a GMP facility in Minneapolis expected to feed the growing demand for reagents in the cell and gene therapy space. The life sciences services and consumables firm reported a 12% growth in sales year-on-year in its third quarter FY2019 within its Protein Sciences segment. The segment – which supplies proteins such as cytokines and growth factors, immunoassays, antibodies and reagents to the biopharma industry – pulled in $138 million in the quarter. Its…